New paper “Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype” published in Cell
RH5.1 is the most advanced vaccine for blood-stage P. falciparum malaria, currently in Phase 2b field efficacy trial. Here we are delighted to share our latest data on how vaccine-induced human antibodies recognise RH5 and kill malaria parasites, now published at Cell. Big congrats to Jordan Barrett and Kirsty McHugh and big thanks to our generous collaborators and partners:
The data define the antigenic landscape of RH5 and show epitope specificity, antibody association rate, and intra-RH5 antibody interactions determine functional anti-parasitic potency. We also identify an exceptionally potent new class of antibody that could be developed as a biologic for malaria prophylaxis.
Big thanks to support from collaborators and funders PATH; USAID; Leidos; NIAID; Kavli Institute for Nanoscience Discovery; The Jenner Institute; The Department of Biochemistry; The Centre for Medicines Discovery (Nuffield Department of Medicine); Oregon Health & Science University; Diamond Light Source; Carterra; Massachusetts Institute of Technology; the UK Medical Research Council; the Wellcome Trust; the NIHR Oxford Biomedical Research Centre; NIH; the Bill & Melinda Gates Foundation and the European Commission.
Also big congrats to our collaborator Josh Tan at NIAID and collaborators with a second paper in the same issue of Cell describing how natural malaria infection can elicit rare but neutralising antibodies to RH5 – a great double take on this leading vaccine antigen!
